Efficacy and Safety of ID-ACT 3302 on the skin wrinkle improvement; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002863

Enrollment

100

Registered

2018-05-11

Start date

2017-04-18

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : take a 350mg capsule of active medication or Placebo. Subjects will orally self-adminster Ildong-acidophilus tyndalizate 3302 capsule 350mg or placebo once, 1 capsule per day for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over skin winkle grade 3 of female can enrolled. (35yrs~59yrs)

Exclusion criteria

Exclusion criteria: ongoing treatment for skin disease (e.g. atophy dermatitis)

Design outcomes

Primary

Measure	Time frame
Skin wrinkle	—

Secondary

Measure	Time frame
Transepidermal Water Loss;Adverse Events	—

Countries

Korea, Republic of

Contacts

Public ContactBeom Kim

Chung-Ang Univerisity Hospital

Outcome results